Use of the NuvaRing hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus.
OBJECTIVE
To evaluate the effect of the vaginally inserted hormone-releasing system NuvaRing on carbohydrate and lipid metabolism and the hemostasis system, over 6 months of use, in late reproductive-age women with type 1 diabetes mellitus (DM).


METHODS
The open randomized study included a total of 25 women with type 1 DM using NuvaRing. Average daily insulin requirements, levels of glycosylated hemoglobin (HbA1c), total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol, the state of coagulation hemostatis and fibrinolytic activity were determined at baseline and after 3 and 6 months of contraception. The control group was composed of 20 age-matched women with type 1 DM using no methods of contraception, as well as 20 apparently healthy women using the NuvaRing device.


RESULTS
Use of the NuvaRing contraceptive system in type 1 DM women in the late reproductive period was shown to exert no clinically significant effect on carbohydrate and lipid metabolism on the background of persistent and satisfactory compensation of carbohydrate metabolism (HbA1c < or = 7.5%), with a neutral impact on the hemostasis system.


CONCLUSIONS
The NuvaRing hormone-releasing system proved to be a reliable and safe means of contraception for late reproductive-age women with type 1 DM.
Grigoryan
Olga R
OR
Federal Facility Endocrinological Research Centre, Russian Academy of Medical Sciences, Moscow, Russia. elena1778@mail.ru
Grodnitskaya
Elena E
EE
Andreeva
Elena N
EN
Chebotnikova
Tatyana V
TV
Melnichenko
Galina A
GA
D000328:Adult; D000375:Aging; D001786:Blood Glucose / Q000187:drug effects*; D050260:Carbohydrate Metabolism / Q000187:drug effects; D003274:Contraceptive Devices, Female; D017135:Desogestrel / Q000031:analogs & derivatives / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*
D001786:Blood Glucose; D017135:Desogestrel; D004338:Drug Combinations; D004997:Ethinyl Estradiol; D006442:Glycated Hemoglobin; C516519:NuvaRing; C517652:hemoglobin A1c protein, human